Patients aged 2 and older have a new option for treating their mild to moderate eczema (atopic dermatitis). AD, often called eczema, is a chronic condition impacting nearly 18 million children and adults in the United States. Approximately 90 percent of people living with AD have the mild to moderate form of the condition.